All News

Other cases discussed in this installment of "Malpractice Consult" include chronic testicular pain following vasectomy and a claim that a spinal tumor should have been found during treatment for post-vasectomy urinary problems.

In this "Coding Q&A" column, Ray Painter, MD, and Mark Painter answer several reader questions involving billing for multiple stones, including replacements for the –59 modifier, use of CPT code 50590, and NCCI guidelines and multiple stones.

In this article, Robert A. Dowling, MD, discusses what you need to know about EHRs and patient safety.

In light the controversial studies linking testosterone replacement therapy to cardiovascular risks, three urologists discuss how their approach to prescribing TRT has (or hasn't) changed.

In this interview, Ian Thompson, MD, answers questions about the downside of diagnosing low-risk prostate cancer, the burdens of active surveillance and how to minimize them, and how his own approach to screening and biopsy have changed.

Ultrasound should be the initial diagnostic imaging test utilized for diagnosing kidney stones in order to reduce the higher radiation exposure associated with computed tomography, say the authors of a recent study.

The Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.

An FDA advisory committee has voted to restrict indications for testosterone replacement therapy and require additional clinical trials to test the safety of the drugs, decisions that have drawn mixed reactions from urologists.

When faced with the difficult prospect of changing one’s normal style of living, the major factors to consider are age, interests, finances, and of course, health issues and concerns.

In this article, Ahmed A. Hussein, MD, and James F. Smith, MD, MS, examine the effect of malignancy and anti-cancer treatment on fertility, review current fertility preservation methods, and offer a preview of fertility preservation techniques that hold future promise.

The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.

The month of September has seen two notable appointments in academic urology, with David F. Penson, MD, MPH, and James McKiernan, MD, both named to department chair positions.

I was driving home from the office last week and realized that I have now been in the "real world" for over a year. As I looked back on the last year, I thought I would share a few of the lessons I've learned as I am curious if others have had a similar experience during their transition from residency to private practice.

Physical activity lowers men’s risk of developing nocturia and should be recommended to patients with the condition, a leading men’s health expert and Urology Times Editorial Council member says.

Metastatic castration-resistant prostate cancer patients whose tumors contain the androgen receptor (AR)-V7 splice variant are less likely to respond to enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA), recent study results indicate.

Low testosterone is often blamed for a lower sex drive and potentially dangerous fat accumulation in men, however researchers from Massachusetts General Hospital report that a lack of estrogen is also to blame. Video provided by Renal & Urology News.

Physicians, including urologists, now have another headache to deal with-making certain information about them published on the Internet by as part of the National Physician Payment Transparency Program (Open Payments) is accurate and not misleading to patients who want to know about the financial benefits their doctors receive from manufacturers of drugs, devices, and biologic and medical supplies.

This video presents a thorough description of all the treatment options available for erectile dysfunction, including their administration, benefits, and limitations.

In this first installment of UrologyTimes.com's new video section, called ‘Y’tube, we present videos from high-volume prosthetic surgeons performing inflatable penile prosthesis (IPP) placement and discussing diagnosis and management of ED. William O. Brant, MD, offers the following general commentary about these procedures, as well as specific comments in the text accompanying each individual video.

In these videos, H. Ballentine Carter, MD, discusses the evidence supporting active surveillance, and Leonard S. Marks, MD, and colleagues outline which men are good candidates for surveillance.

Results of a study that included approximately 50,000 patients point to an association between kidney stones and incident cardiovascular disease and stroke.

Men who eat over 10 portions a week of tomatoes have an 18% lower risk of developing prostate cancer, according to a newly published study from the United Kingdom.

As it becomes apparent that more prostate cancers are clinically insignificant than previously believed, the role of active surveillance in the management of men with low-risk prostate cancer merits expansion.

This letter to the editor is in response to an editorial by J. Stuart Wolf, Jr., MD (“Robotic radical nephrectomy: Really?,” July 2014, page 6). The editorial concerned the article, “Use of robotic RN rising, despite unclear advantages” (July 2014, page 9).

Steven A. Kaplan, MD, introduces #LetsTalkMensHealth, a novel new section in Urology Times focused on men’s health.

Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.

Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.

Patients with interstitial cystitis/bladder pain syndrome who have low bladder capacity have a significantly different gene expression profile than both IC/BPS patients with normal bladder capacity and those without the condition, researchers reported in a recently published pilot study.

Presentations of phase III data at the American Society of Clinical Oncology annual meeting in Chicago further support the conclusion that the oral androgen receptor inhibitor enzalutamide (XTANDI) addresses an unmet therapeutic need for metastatic castration-resistant prostate cancer in the pre-chemotherapy setting.

A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.